MUMBAI, India — Glenmark Pharmaceuticals Inc. USA has received final approval from the Food and Drug Administration for nitroglycerin sublingual tablets in strengths of 0.3 mg, 0.4 mg and 0.6 mg.

Glenmark said Wednesday that its nitroglycerin product, which is placed under the tongue, is a generic version of Nitrostat sublingual tablets (0.3 mg, 0.4 mg and 0.6 mg) from Pfizer Inc.

A nitrate that widens blood vessels, nitroglycerin is used to treat or prevent angina, or attacks of chest pain.

Nitrostat sublingual tablets (0.3 mg, 0.4 mg and 0.6 mg) total U.S. sales of approximately $112.7 million for the 12-month period ended in July, according to IMS Health sales data reported by Glenmark.